Mon panier

Biotinylated Human Integrin isoform alpha-7X2B beta 1 (ITGA7X2B&ITGB1) Heterodimer Protein, Avitag™&His,Avitag™

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
IT1-H82W5-25ug
$415.00
IT1-H82W5-200ug
$1880.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    Integrin isoform alpha-7X2B beta 1, ITGA7X2BB1, ITGA7X2B&ITGB1

  • Source

    Biotinylated Human ITGA7X2B&ITGB1 Heterodimer Protein, Avitag&His,Avitag (IT1-H82W5) is expressed from human 293 cells (HEK293). It contains AA Phe 34 - Trp 1038 (ITGA7X2B) & Gln 21 - Asp 728 (ITGB1) (Accession # Q13683-7 (ITGA7X2B) & P05556-1 (ITGB1)).

    Predicted N-terminus: Phe 34 (ITGA7X2B) & Gln 21 (ITGB1)

    Request for sequence
  • Molecular Characterization

    Integrin isoform alpha-7X2B beta 1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    Biotinylated Human ITGA7X2B & ITGB1 Heterodimer Protein, produced by co-expression of ITGA7X2B and ITGB1, has a calculated MW of 116.9 kDa (ITGA7X2B) and 86.7 kDa (ITGB1). Subunit ITGA7X2B is fused with an acidic tail and an Avi tag (Avitag™) at the C-terminus and subunit ITGB1 contains a basic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™). The non-reducing (NR) protein migrates as 100-115 kDa due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    Integrin isoform alpha-7X2B beta 1 SDS-PAGE

    Biotinylated Human ITGA7X2B&ITGB1 Heterodimer Protein, Avitag&His,Avitag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • Bioactivity-SPR

     Integrin isoform alpha-7X2B beta 1 SPR

    Biotinylated Human ITGA7X2B&ITGB1 Heterodimer Protein, Avitag&His,Avitag (Cat. No. IT1-H82W5) immobilized on CM5 Chip can bind Human Laminin 211 Protein, premium grade (Cat. No. LA8-H5263) with an affinity constant of 600 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Integrin alpha-7/beta-1 is the primary laminin receptor on skeletal myoblasts and adult myofibers, which is highly expressed in cardiac muscle, skeletal muscle and smooth muscle cells, and localizes to Z-disc and costamere structures. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity. Isoform Alpha-7X2B and isoform Alpha-7X1B promote myoblast migration on laminin 1 and laminin 2/4, but isoform Alpha-7X1B is less active on laminin 1 (In vitro). ITGA7 has been shown to interact with Merosin, ITGB1, FHL2 and FHL3.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Integrin alpha7/beta1

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    0 Détails

  • Étape de développement la plus élevée:

    Preclinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte